Possible antiretroviral therapy-warfarin drug interaction.

Possible antiretroviral therapy-warfarin drug interaction. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Possible antiretroviral therapy-warfarin drug interaction. Abstract Text:

Abstract Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) has resulted in significant morbidity and mortality reductions. Lifelong antiretroviral therapy must be incorporated into each patient's medical regimen. Patients with HIV may also have simultaneous chronic medical conditions, resulting in the possibility of complex drug-drug interactions. We report a possible drug-drug interaction between HAART and warfarin in two patients, as assessed by the Naranjo adverse drug reaction probability scale and the Drug Interaction probability scale. Both patients' pharmacotherapy regimens included a nonnucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, or a protease inhibitor, nelfinavir or lopinavirritonavir, and two nucleoside analogs. In both patients, high warfarin doses were required to maintain therapeutic international normalized ratios (INRs). Warfarin has two enantiomers, R-and S-warfarin, which are substrates primarily of cytochrome P450 (CYP) 3A4 (R-warfarin), CYP1A2 (R-warfarin), and CYP2C9 (S-warfarin). Protease inhibitors and NNRTIs have variable effects on CYP: induction, inhibition, or mixed. The increased warfarin doses required in these two patients may have been caused by induction of CYP3A4 by nevirapine, CYP2C9 by nelfinavir, or CYP2C9 by lopinavir-ritonavir. Thus, practitioners should prudently monitor INRs in patients receiving warfarin with concomitant HAART that includes either a protease inhibitor or an NNRTI.

Possible antiretroviral therapy-warfarin drug interaction. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Possible antiretroviral therapy-warfarin drug interaction. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Pharmacotherapy

VOLUME: 28

Page Numbers: 945-9

Journal Abbreviation: Pharmacotherapy

ISSN: 0277-0008

DAY: 25

MONTH: Jul

YEAR: 2008

Possible antiretroviral therapy-warfarin drug interaction. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8111305

Possible antiretroviral therapy-warfarin drug interaction. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Possible antiretroviral therapy-warfarin drug interaction. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Possible antiretroviral therapy-warfarin drug interaction.

AFFILIATION: 1 Departments of Pharmacy, Virginia Commonwealth University Medical Center; Virginia Commonwealth University, Richmond, Virginia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharmacotherapy

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Possible antiretroviral therapy-warfarin drug interaction Related Publications

• "I will do it if it will help others:" motivations among patients taking part in qualitative studies in palliative care.
• Cancer Trajectories at the End of Life: is there an effect of age and gender?
• Coronary stenting in acute myocardial infarction--patency demonstrated postmortem.
• Death from renal failure eighty years on: how far have we come?
• Delayed rupture of false aneurysm following a femoral fracture.
• Emotion, suffering, and hope: commentary on "How much emotion is enough"?
• Experiences of breathlessness: a systematic review of the qualitative literature.
• Is the qualitative research interview an acceptable medium for research with palliative care patients and carers?
• Meeting the communication and information needs of chronic heart failure patients.
• Methodological considerations for end-of-life research in patients with chronic kidney disease.
• Modelling services to meet the palliative care needs of chronic heart failure patients and their families: current practice in the UK.
• Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases.
• Not Available
• Possible antiretroviral therapy-warfarin drug interaction.
• Potential cardiotoxicity with the use of DuP-941: a case report.
• Primary carcinoma of the liver in Africa.
• Proceedings: The epidemiological program of the International Agency for Research on Cancer.
• Profile of the cardiovascular specialist physician workforce in Canada, 2004.
• Quality criteria valuable with slight modification.
• Symptom prevalence among people affected by advanced and progressive neurological conditions--a systematic review.
• Symptoms in Advanced Renal Disease: A Cross-Sectional Survey of Symptom Prevalence in Stage 5 Chronic Kidney Disease Managed without Dialysis.
• The development of an unconstrained elbow arthroplasty. A clinical review.
• The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy.
• The time bomb of Aboriginal health: can the fuse get any shorter?
• Training to maximize economy of motion in running gait.
• Two simple methods for determining gait events during treadmill and overground walking using kinematic data.
• Use of the palliative outcome scale in Argentina: a cross-cultural adaptation and validation study.
• Where people die (1974--2030): past trends, future projections and implications for care.
• Women's help-seeking behaviour at the onset of myocardial infarction.
• [Not Available.]